top of page

Moving Beyond Parkinson's: The Promise of High-Intensity Exercise

Parkinson's disease, a condition that progressively impairs movement and balance, poses significant challenges for those affected. This neurodegenerative disorder is marked by the loss of dopamine-producing neurons, leading to symptoms such as tremors, rigidity, and movement difficulties. Despite advances in treatment, therapies modifying the underlying disease mechanism remain elusive, leaving a gap filled with medications aimed at symptom management rather than disease alteration. Yet, hope may lie in an unexpected ally: exercise.


A noteworthy study has explored the impact of an innovative exercise program, Beat Parkinson’s Today, devised by Michelle Hespeler, a person living with Parkinson's. This study involved ten individuals in the early stages of Parkinson's, engaging in high-intensity exercise sessions over a six-month period, all conducted online. The regimen was designed to maintain high heart rates through functional interval training, monitored by heart rate trackers and fitness wearables.


 elder Pacific Islander woman, a younger Caucasian man, and an Asian woman happily chatting after completing their workou

The preliminary findings from the study are striking. Brain imaging conducted before and after the program revealed a substantial increase in the levels of dopamine transporters and neuromelanin in the substantia nigra, a part of the brain severely impacted by Parkinson's. The significance of these results lies in the roles of dopamine transporters in facilitating crucial movement coordination and neuromelanin's function in protecting neurons. The research documented a 19.95% increase in dopamine transporter levels and a 5.3% rise in neuromelanin concentration among participants, marking a stark contrast to the decline typically seen in patients with Parkinson’s, who experienced reductions in these critical markers. This suggests that regular, intensive exercise counteracts the typical decline in dopamine signalling in Parkinson's progression.


It's important to highlight some study limitations, including the lack of a control group, which makes it difficult to definitively attribute the observed benefits to the exercise program alone. Additionally, the study focused on early-stage Parkinson's patients who were physically capable and motivated to undertake a rigorous exercise regimen, indicating that these findings might not be universally applicable.


The study’s insights into the potential of exercise to impact Parkinson’s disease are intriguing, especially in the context of ongoing research into the benefits of physical activity for neurological health. Exercise-induced hormones like Irisin, which is known to cross the blood-brain barrier and may influence brain function, represent a fascinating area of study. This hormone, linked to metabolism and fat reduction, could also mediate exercise's positive effects on the brain.


While this research provides valuable evidence of exercise's potential benefits for Parkinson's patients, it also underscores the need for further exploration into which types of physical activity might be most effective and how these can be adapted to suit individuals at different stages of the disease.


In conclusion, this study isn't the first to highlight the benefits of exercise for Parkinson's disease, but it significantly reinforces the notion that physical activity should be a cornerstone of treatment strategies. The importance of this research lies in its contribution to the growing body of evidence that exercise is more than just beneficial—it's a critical component of managing Parkinson's. This study adds another layer of proof that regular, intensive exercise can make a meaningful difference in the prevention and progression of the disease. As we continue to explore the role of exercise in Parkinson's treatment, it's becoming increasingly clear that integrating physical activity into patient care plans is not just advisable; it's essential for improving the lives of those living with Parkinson's.

Dr Victor Dieriks

Group Leader Synuclein Lab

Centre for Brain Research

The University of Auckland, New Zealand



bottom of page